Elanco Animal Health (ELAN) has just rolled out its Advantage Collar for Dogs, a four month, over the counter flea, tick, and mosquito protection product that broadens its established pet health lineup.
See our latest analysis for Elanco Animal Health.
The new Advantage Collar launch comes as Elanco’s shares trade at $23.86, with short term momentum reflected in a 1 day share price return of 3.16% and a year to date share price return of 5.95%. The 1 year total shareholder return of 174.88% and 3 year total shareholder return of 149.84% point to a strong rerating over time, despite a 20.47% total shareholder return decline over five years and some recent 90 day share price softness.
If this kind of product launch has you thinking more broadly about where growth could show up next in healthcare and tech, it may be worth scanning 34 healthcare AI stocks
With Elanco trading at $23.86, sitting below an average analyst price target of $28.77 and with some recent 90 day share price softness, you have to ask: is there still upside here or is future growth already priced in?
Most Popular Narrative: 17.1% Undervalued
Elanco’s most followed narrative points to a fair value of $28.77 against the current $23.86 share price, framing the Advantage Collar launch within a broader rerating story.
Elanco anticipates an acceleration in organic constant currency revenue growth of 4% to 6%, driven by innovation and market expansion. This will positively impact revenue growth.
Want to understand why a modest revenue step up and a margin rebuild could be associated with a far richer future earnings multiple than today? The full narrative explains how product launches, portfolio reshaping, and international mix are linked to that higher fair value, and which assumptions really carry the weight.
Result: Fair Value of $28.77 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, this hinges on smooth execution, and FX pressure or slower than expected uptake of new products such as Zenrelia and Credelio Quattro could quickly test that thesis.
Find out about the key risks to this Elanco Animal Health narrative.
Next Steps
The narrative so far leans positive, but the real question is how it lines up with your own view of risk and reward. Take a moment to review the company’s 4 key rewards
Looking for more investment ideas?
If you stop with just one company, you risk missing other opportunities that match your goals, so take a few minutes to scan broader options.
- Target potential value by reviewing companies screened for 55 high quality undervalued stocks that may align with your return expectations and risk appetite.
- Prioritise resilience by focusing on businesses in the solid balance sheet and fundamentals stocks screener (41 results) that may better handle shocks and funding needs.
- Seek steady income by checking out the 10 dividend fortresses that could fit a cash flow focused portfolio.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com